STXS
Stereotaxis, Inc.
STXS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
STXS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
STXS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
STXS PE Valuation
STXS has no meaningful PE right now: it lost money over the past year.
STXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect STXS's losses to shrink, with revenue growing.
STXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.24 | +$0.05 |
| Q1 2026 | -$0.24 | +$0.07 |
| Q4 2025 | -$0.25 | +$0.05 |
| Q3 2025 | -$0.28 | -$0.01 |
| Q2 2025 | -$0.29 | -$0.03 |
| Q1 2025 | -$0.31 | -$0.05 |
| Q4 2024 | -$0.30 | -$0.03 |
| Q3 2024 | -$0.27 | $0.00 |
STXS is still losing money, but less than at its worst: $0.24 per share over the past year, against $0.31 at its worst in early 2025.
STXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.7M | -13% |
| Q1 2026 | $6.3M | -16% |
| Q4 2025 | $8.6M | +36% |
| Q3 2025 | $7.5M | -19% |
| Q2 2025 | $8.8M | +95% |
| Q1 2025 | $7.5M | +8.6% |
| Q4 2024 | $6.3M | +39% |
| Q3 2024 | $9.2M | +18% |
STXS's revenue has slid since its 2024 peak: $8M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -60% | -14 points |
| Q1 2026 | -95% | -16 points |
| Q4 2025 | -65% | +55 points |
| Q3 2025 | -88% | -19 points |
| Q2 2025 | -45% | +89 points |
| Q1 2025 | -79% | -10 points |
| Q4 2024 | -120% | -4.1 points |
| Q3 2024 | -69% | +3.3 points |
STXS's operating margin was −60% last quarter, down 14 points from the same quarter a year ago.
STXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | -$1.7M |
| Q4 2025 | -$4M | -420% |
| Q3 2025 | -$4.2M | +$135K |
| Q4 2024 | $1.3M | +$3.7M |
| Q3 2024 | -$4.3M | -$3.4M |
| Q4 2023 | -$2.4M | +$482K |
| Q3 2023 | -$977K | +$1.8M |
| Q2 2023 | -$2.9M | -$1.2M |
STXS has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
STXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | +14% | +12.1M shares |
| 3 years | +23% | +19M shares |
| 5 years | +32% | +24.5M shares |
| Available history | +56% | +35.7M shares |
STXS has 100M diluted shares, up 14% from a year ago.
STXS Net Leverage
STXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
STXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 18.5 | Oversold |
STXS's weekly RSI is 31 (neutral) and its Stochastic is 18 (oversold).
STXS PE vs Healthcare Sector
STXS has no meaningful PE right now: it lost money over the past year.
STXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 19% below |
| 20 week MA | $1.28 | 34% below |
| 50 week MA | $1.76 | 52% below |
| 100 week MA | $2.05 | 59% below |
| 200 week MA | $2.02 | 58% below |
STXS is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
STXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $5.14 | +2.2% |
| 2021 | $5.14 | $6.26 | +22% |
| 2022 | $6.26 | $2.03 | -68% |
| 2023 | $2.03 | $1.75 | -14% |
| 2024 | $1.75 | $2.29 | +31% |
| 2025 | $2.29 | $2.46 | +7.4% |
| 2026 YTD | $2.46 | $0.85 | -65% |
STXS is down 65% so far in 2026, after finishing higher in four of the previous six years.